Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20356016 | 0.83 | CES2 (0.39) | CES2CES1BCHEGPR84 | |
| SCHEMBL29489580 | 0.79 | CES2 (0.53) | CES2CES1BCHEGPR84CA3 | |
| SCHEMBL45430 | 0.79 | CES2 (0.53) | CES2CES1BCHEGPR84CA3 | |
| SCHEMBL30257704 | 0.77 | HPRT1 (0.64) | — | |
| SCHEMBL7295982 | 0.77 | CES2 (0.35) | CES2CES1BCHE | |
| SCHEMBL24536159 | 0.77 | ALDH1A1 (0.59) | — | |
| SCHEMBL8723797 | 0.77 | CES2 (0.31) | CES2CES1BCHE | |
| SCHEMBL24536156 | 0.77 | IDO1 (0.46) | CES2CES1BCHECA6 | |
| SCHEMBL8723799 | 0.77 | CES2 (0.31) | CES2CES1BCHE | |
| SCHEMBL26190035 | 0.77 | HPRT1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | OSAKA UNIVERSITY (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | OSAKA UNIVERSITY (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564245-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | Osaka University (JP) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018123207-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | 国立大学法人大阪大学 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | CYP24A1, CYP26B1, CYP21A2 | CES2 1688/4885CES1 744/4885MIF 4330/4885 |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | CYP24A1, CYP26B1, CYP21A2 | CES2 1688/4885CES1 744/4885MIF 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.